News

Public · Published

Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations

Boston Scientific reported Q3 2026 revenue of $5.14 billion, up 1.4% year on year and above analysts' consensus estimate of $5.07 billion. Its Q4 2026 revenue guidance midpoint of $5.18 billion came in 4.5% below analysts' consensus estimates.

Published:

Updated:

What happened

Boston Scientific reported Q3 2026 revenue of $5.14 billion, up 1.4% year on year and above analysts' consensus estimate of $5.07 billion. Its Q4 2026 revenue guidance midpoint of $5.18 billion came in 4.5% below analysts' consensus estimates.

Confirmed

Global impact / market context

The quarterly beat shows demand held up, but the weak next-quarter sales guidance suggests growth may slow ahead. Because Boston Scientific also lowered its full-year adjusted profit guidance, investors could question whether the company's sales outlook supports its earnings.

Analyst inference

Boston Scientific said it managed a cybersecurity incident this year, which means an event affecting its computer systems. Its operating profit per sale fell to 16.1% from 20.7% a year earlier, a sign that costs are taking a larger share of revenue.

Analyst inference

What to watch

  1. Watch whether Boston Scientific's Q4 2026 revenue lands near its $5.18 billion guidance midpoint or closer to analysts' higher consensus estimate. Confirmed
  2. Management could face questions about restoring operations after the cybersecurity incident and whether related costs or disruptions keep weighing on sales and operating profit per sale. Proposed
  3. Investors may compare the lowered full-year adjusted profit guidance of $3.17 with the Q4 revenue outlook to judge whether cost pressures are easing or persist. Analyst inference

Evidence